首页> 外文期刊>American Journal of Hematology >Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors
【24h】

Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors

机译:小儿再生障碍性贫血和难治性血细胞减少症:回顾性评估评估结局和组织形态学预测指标

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Pediatric acquired aplastic anemia (AA) is a bone marrow disorder that is difficult to distinguish from inherited bone marrow failure syndromes and hypocellular refractory cytopenia of childhood (RCC). Historically, patients with hypocellular RCC have been given the diagnosis of AA. To assess the clinical and histologic distinction between RCC and AA, we performed a retrospective analysis of 149 patients previously diagnosed with AA between 1976 and 2010. We evaluated event free survival (EFS), overall survival (OS), response rates to immunosuppressive therapy, treatment-related toxicities and clonal evolution. The 5-year EFS and OS were 50.8%+/- 5.5% and 73.1%+/- 4.7%, respectively. Patients with very severe AA had worse OS compared to patients with severe and moderately severe AA. Seventy-two patients had diagnostic pathology specimens available for review. Three pediatric hematopathologists reviewed and reclassified these specimens as AA, RCC or Other based on 2008 WHO Criteria. The concordance between pathologists in the diagnosis of AA or RCC was modest. RCC was associated with a trend toward improved OS and EFS and was not prognostic of immunosuppression therapy treatment failure. There was a low rate of clonal evolution exclusively associated with moderately severe AA. Our findings indicate that a diagnosis of RCC is difficult to establish with certainty and does not predict outcomes, calling into question the reproducibility and clinical significance of the RCC classification and warranting further studies. Am. J. Hematol. 90:320-326, 2015. (c) 2015 Wiley Periodicals, Inc.
机译:小儿获得性再生障碍性贫血(AA)是一种骨髓疾病,很难与儿童遗传性骨髓衰竭综合征和儿童低细胞难治性血细胞减少症(RCC)区别开来。从历史上看,患有细胞减少的RCC的患者已被诊断为AA。为了评估RCC和AA之间的临床和组织学区别,我们对1976年至2010年以前诊断为AA的149例患者进行了回顾性分析。与治疗有关的毒性和克隆进化。 5年EFS和OS分别为50.8%+ /-5.5%和73.1%+ /-4.7%。与患有严重和中度严重AA的患者相比,患有严重AA的患者的OS较差。七十二名患者的诊断病理学标本可供检查。三名儿科血液病理学家根据2008年WHO标准对这些标本进行了审查,并将其重新分类为AA,RCC或其他。病理学家在诊断AA或RCC方面的一致程度不高。 RCC与OS和EFS改善趋势有关,并且不能预示免疫抑制疗法治疗失败。仅与中度严重AA相关的克隆进化率较低。我们的发现表明,RCC的诊断很难确定且不能预测结果,这对RCC分类的可重复性和临床意义提出了疑问,值得进一步研究。上午。 J. Hematol。 90:320-326,2015.(c)2015威利期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号